We are proud to announce that PhenoPath is now a Quest Diagnostics Company.

CD19 pin

IHC

CD19

Methodology: IHC

Clinical Significance:
CD19, like the CD79 complex and cytoplasmic CD22, is a pan-B-lineage antigen that is first expressed in very early B-lymphoid progenitors, and continues to be expressed at variable levels through terminal B-lymphoid differentiation in plasma cells. With the exception of true plasma cell neoplasms and classical Hodgkin lymphoma, the great majority of mature and immature B-lymphoid neoplasms express CD19. Some neoplasms such as hairy cell leukemia overexpress CD19, while others such as follicular lymphoma typically underexpress CD19. Rare non-B-lymphoid neoplasms express CD19, most notably acute myeloid leukemia (AML) bearing the t(8;21). Subcellular Localization: Mainly membranous; partially cytoplasmic

Organ: Blood/Bone Marrow

Disease State: B Cell Non-Hodgkin Lymphoma (not otherwise classified)

CPT Code(s): 88342 or 88341. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Turnaround Time: Within 1-2 business days of receipt

Schedule: Monday - Friday

Specimen Requirements:
• Formalin-fixed, paraffin-embedded (FFPE) tissue block or cell block - OR - • 1 unstained slide for each test requested plus 3-4 additional unstained slides cut at 4µm